



# Provider Update

December 20, 2022

DOH Deputy Secretary Laura C. Parajón, M.D., M.P.H  
Infectious Disease Bureau Chief Dan Burke  
IDB Medical Director Miranda Durham, M.D.

# NM DOH Mission

*To ensure health equity, we work with our partners to promote health and well-being, and improve health outcomes for all people in New Mexico.*

## Goals



**We expand equitable access** to services for all New Mexicans



**We ensure safety** in New Mexico healthcare environments



**We improve health status** for all New Mexicans




**We support each other** by promoting an environment of mutual respect, trust, open communication, and needed resources for staff to serve New Mexicans and to grow and reach their professional goals

# COVID-19 Overview




# COVID-19 Community Levels

A measure of the impact of COVID-19 illness on health and healthcare systems



data through 12/17/22




data through 12/4/22

COVID-19 Community Levels in US by County			
	Total	Percent	% Change
High	295	9.19%	- 0.1%
Medium	1124	35.02%	- 0.22%
Low	1791	55.79%	0.33%


[How are COVID-19 Community Levels calculated?](#)

# Community Transmission - CDC

the map for healthcare facilities



12/17/22




12/4/22

## Community Transmission in US by County

	Total	Percent	% Change
High	2406	74.67%	20.86%
Substantial	533	16.54%	- 10.92%
Moderate	202	6.27%	- 8.72%
Low	81	2.51%	- 1.21%

[How is community transmission calculated?](#)


# COVID Variants



<https://covid.cdc.gov/covid-data-tracker/#variant-proportions>



# CDC NowCast



<https://covid.cdc.gov/covid-data-tracker/#variant-proportions>

## COVID in NM - CASES

case counts do  
not include  
at-home positive  
tests

### Community risk level metrics

WEEKLY NEW REPORTED CASES


● **132.6** PER 100K

WEEKLY COVID ADMISSIONS

● **8.9** PER 100K

PATIENTS W/ COVID

● **5.4%** OF ALL BEDS



Over the last week, New Mexico had 2,774 new reported cases (**132.6** for every 100,000 residents). Reported cases do not include all at-home positive tests. Grading is not applied to weekly new reported cases prior to April 18, 2022, indicated by the dotted line. This date marks our change to measure community risk levels, a framework that is only relevant for the current phase of the pandemic. [About this data](#)

Share



## COVID in NM - "R effective"

### Transmission metrics

DAILY NEW CASES PER 100K


**18.9**

INFECTION RATE

**0.90**

POSITIVE TEST RATE

**14.9%**



On average, each person in New Mexico with COVID is infecting 0.90 other people. If this number is over 1.0, it means that the total number of COVID cases is growing. About this data

Share

## All metrics

METRIC


Admissions (weekly COVID admission... ▼

PAST # OF DAYS ▼

180

LOCATIONS ▼

New Mexico; New York; Arizona; U... ▼




## All metrics


METRIC  
Admissions (weekly COVID admission... ▼

PAST # OF DAYS  
All time ▼


LOCATIONS  
New Mexico; New York; Arizona; U... ▼








[https://covid.cdc.gov/covid-data-tracker/#trends\\_weeklydeaths\\_7dayeddiagnosed\\_00](https://covid.cdc.gov/covid-data-tracker/#trends_weeklydeaths_7dayeddiagnosed_00)





- During April–June 2022, 58.7% of blood donors had antibody evidence of previous infection (compared with 48.8% in Jan–March 2022), and 94.3% had antibodies from vaccination, infection, or both (compared with 92.2% in Jan–March 2022).
- Infection-induced seroprevalence continues to be higher in younger people compared with older people; in people living in the South and Midwest compared with people living in the West and Northeast; and in Non-Hispanic Black and Hispanic populations compared with non-Hispanic White populations. All groups had high combined seroprevalence from vaccination, infection, or both.
  - Infection-induced seroprevalence in people ages 16-29 years was 72.1% compared with 32.6% in people aged 65 years and older.
  - Infection-induced seroprevalence among Hispanic people was 62.5%; 65.0% among Non-Hispanic Black people; and 58.5% among non-Hispanic White people.
  - April to June 2022 infection-induced seroprevalence by state ranged from 44.4% in Oregon to 78.4% in South Dakota.

[CDC COVID Data Tracker: Nationwide Blood Donor Seroprevalence](#)



# Covid Changes

- Federal Public Health Emergency - through June 2023?
- Medicaid extension likely ending April 1
- Curative notified NMDOH that they will stop testing 12/28/22
- [Project ACT](#) - extended to end of June 2023
- FDA VRBPAC meeting in January 26, 2023 - may discuss using bivalent for the primary series
- Remaining J&J will not be available in the US after February 2023
- Commercialization: VFC will cover COVID vaccine


## iHealth Test Kit Expiration Extension

As of July 8th, 2022, the FDA extended the shelf-life of iHealth COVID-19 Antigen Rapid Tests to 12 months. Please [click here](#) for details or to look up new expiration dates by lot numbers.



## Get your **FREE** at-home test kits!

We are offering free, rapid, at-home COVID-19 test kits to residents of eligible communities while supplies last. **Enter your zip code to see if tests are available in your area:**



# Vaccine Updates





# It's a Match!

“The majority of influenza viruses tested are in the same genetic subclade as and antigenically similar to the influenza viruses included in this season’s influenza vaccine.”

<https://www.cdc.gov/flu/weekly/index.htm>



# Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022

Early Release / November 22, 2022 / 71

Ruth Link-Gelles, PhD<sup>1</sup>; Allison Avrich Ciesla, PhD<sup>1,2</sup>; Katherine E. Fleming-Dutra, MD<sup>1</sup>; Zachary R. Smith, MA<sup>3</sup>; Amadea Britton, MD<sup>1</sup>; Ryan E. Wiegand, PhD<sup>1</sup>; Joseph D. Miller, PhD<sup>3</sup>; Emma K. Accorsi, PhD<sup>1,4</sup>; Stephanie J. Schrag, DPhil<sup>1</sup>; Jennifer R. Verani, MD<sup>1</sup>; Nong Shang, PhD<sup>1</sup>; Gordana Derado, PhD<sup>1</sup>; Tamara Pilishvili, PhD<sup>1</sup> ([VIEW AUTHOR AFFILIATIONS](#))

**An updated (bivalent) COVID-19 booster provides *additional protection* against symptomatic COVID-19 illness\***

**COVID-19 VACCINE DRIVE -THRU**

**COVID-19 spread has increased during the last two winters; stay up to date with COVID-19 vaccination**

\* Among immunocompetent adults with COVID-19-like symptoms, the vaccination status of 121,687 adults with a positive COVID-19 test was compared to that of 238,939 adults with a negative COVID-19 test

[bit.ly/mm7148e1](https://www.cdc.gov/mmwr/volumes/71/wr/mm7148e1.htm#:~:text=Among%20symptomatic%20adults%20who%20received,or%204%20monovalent%20vaccines%20alone.)  
NOVEMBER 22, 2022

**MMWR**


Among symptomatic adults who received testing for SARS-CoV-2 infection at pharmacies nationwide during September 14–November 11, 2022, bivalent mRNA vaccines provided additional protection against infection compared with previous vaccination with 2, 3, or 4 monovalent vaccines alone.

Generally, Vaccine Efficacy is similar regardless of number of monovalent doses received. Overall, time since last monovalent dose in the comparison group matters more than number of doses.

<https://www.cdc.gov/mmwr/volumes/71/wr/mm7148e1.htm#:~:text=Among%20symptomatic%20adults%20who%20received,or%204%20monovalent%20vaccines%20alone.>



## Omicron Boosters Administered by Day in NM



**321,064 doses as of 12/11**

41.6% of people 65+ with a primary series have gotten a Bivalent Booster



# GET BOOSTED TODAY



COVID vaccines **lose power** like batteries.  
**Recharge your protection.**

Schedule your booster today at:  
[vaccinenm.org](https://vaccinenm.org)



FDA NEWS RELEASE

# Coronavirus (COVID-19) Update: FDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age



For Immediate Release: December 08, 2022


- Moderna Bivalent for 6 month - 5 year olds was authorized as a booster dose following a Moderna primary series ONLY
- Pfizer Bivalent for 6 months - 4 years old was not authorized as a booster (but as a 3rd primary series dose)



# Pediatric Schedule: Ages 6 months–4 Years


## Ages 6 months–4 years

(Primary Series: Moderna)



## Ages 6 months–4 years

(Primary Series: Pfizer-BioNTech)




No booster dose authorized



## Pediatric Schedule: Age 5 Years


### Age 5 years

(Primary Series:  
Moderna)



### Age 5 years

(Primary Series:  
Pfizer-BioNTech)



Regardless of previous monovalent booster doses given






## Pediatric Schedule: Ages 6–11 Years


### Ages 6–11 years

(Primary Series:  
Moderna or Pfizer-  
BioNTech)




# COVID-19 Vaccination Schedule Infographic for People who ARE Moderately or Severely Immunocompromised


## People ages 6 months through 4 years




## People age 5 years




## People ages 6 through 11 years



## People ages 12 years and older



## People ages 18 years and older who previously received Janssen primary series dose†




<https://www.cdc.gov/vaccines/covid-19/images/COVID19-vaccination-schedule-immunocompromised.png>

# Pfizer-BioNTech:

## Children Aging 4 to 5 Years During the Primary Series


**Scenario 1:** If a 3-dose series is initiated, it must be completed, even if a child ages up between doses 1 and 2.



# Pfizer-BioNTech:

## Children Aging 4 to 5 Years During the Primary Series

**Scenario 2:** If a 3-dose series is initiated, it must be completed, even if a child ages up between doses 2 and 3.






# Pfizer-BioNTech:

## Children Aging 4 to 5 Years During the Primary Series

**Scenario 3:** If a 2-dose primary series is initiated, it must be completed using the product for people ages 5–11 years (orange cap)




## Children Transitioning from a Younger to Older Age Group who **ALREADY** Received a Bivalent Booster Dose

- Only 1 bivalent booster dose total is currently authorized.
- Children transitioning from a younger to older age group who have already received 1 bivalent booster dose CANNOT get a second bivalent booster dose.
- Example: A child age 5 years received the Moderna primary series and Moderna bivalent booster. When this child turns age 6 years, they do not get another bivalent booster. Once a child receives 1 bivalent booster dose, no additional booster doses are indicated at this time.



# Mixed Series For Children Ages 6 Months–4 Years

- Children ages 6 months–4 years who receive different mRNA products for the first 2 doses of an mRNA COVID-19 vaccine series should follow a 3-dose schedule. A third dose of either a monovalent Moderna vaccine or a bivalent Pfizer-BioNTech vaccine should be administered at least 8 weeks after the second dose to complete the 3-dose primary series. These children are currently not eligible for a booster dose.



# COVID-19 Vaccine Products

- Moderna: 5 products
- Pfizer-BioNTech: 6 products
- Novavax: 1 product
- Janssen: 1 product



<https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html>

<https://www.cdc.gov/vaccines/hcp/admin/downloads/vaccine-administration-preventing-errors.pdf>




# COVID-19 Vaccine Product Guide



**Check vaccine labels and [EUA fact sheets](#) before use to avoid mix-ups.**

EUA fact sheets supersede info on vials and carton. Refer to [CDC Product Guide](#) for more information.

Pfizer			
Infant/Toddler 6 months– 4 years*	Bivalent Dose 3 6 months– 4 years		Pediatric Primary Series 5–11 years
			
	"Bivalent" on label		"Bivalent" on label

Packaging	Maroon Cap	Maroon Cap	Orange Cap	Orange Cap
Doses Per Vial	10 doses	10 doses	10 doses	10 doses
Carton Size	100 doses	100 doses	100 doses	100 doses
Min. Standard Order	100 doses	100 doses	100 doses	100 doses
<a href="#">NDC-Unit of Use (vial)</a>	59267-0078-01	59267-0609-01	59267-1055-01	59267-0565-01
CVX Code	219	302	218	301

**Storage Limits Before Puncture:** Label vaccine with expiration and use-by dates.

ULT (-90°C to -60°C)	Up to 18 months from manufacture date.
Thermal Shipper	
Freezer	
Refrigerator (2–8°C)	Up to 10 weeks (write the date on carton)
Expiration Date	18 months from manufacture date printed on vial and carton or check <a href="#">product website</a> .

## Administration






Diluent (supplied)	2.2 mL per vial		1.3 mL per vial	1.3 mL per vial
Dose Volume– Primary/Additional	0.2 mL† (3 mcg dose)		0.2 mL† (10 mcg dose)	N/A
Dose Volume–	N/A		<b>Do not use for</b>	0.2 mL†

# COVID-19 Vaccine Product Guide



**Check vaccine labels and [EUA fact sheets](#) before use to avoid mix-ups.**

EUA fact sheets supersede info on vials and carton. Refer to [CDC Product Guide](#) for more information.

Moderna				
Infant/Toddler 6 months– 5 years	Bivalent Booster 6 months– 5 years	Pediatric Primary Series 6–11 years*	Adol/Adult Primary Series 12+ years	Bivalent Booster 6+ years
				
Magenta Border	"Bivalent" On label	Purple Border	Light Blue Border	Gray Border

Packaging	Dark Blue Cap	Dark Pink Cap	Dark Blue Cap	Red Cap	Blue Cap
Doses Per Vial	10 doses	2 doses	5 doses	10–11 doses	5–10 doses
Carton Size	100 doses	20 doses	50 doses	100 doses	50–100 doses
Min. Standard Order	100 doses	100 doses	100 doses	100 doses	100 doses
<a href="#">NDC-Unit of Use (vial)</a>	80777-0279-05	80777-0283-02	80777-0275-05	80777-0273-10	80777-0282-05
CVX Code	228	230	221	207	229

**Storage Limits Before Puncture:** Label vaccine with expiration and use-by dates.

ULT (-90°C to -60°C)	
Thermal Shipper	
Freezer	Until expiration at -50°C to -15°C (-58°F to 5°F)
Refrigerator	Up to 30 days (not to exceed expiration date) at 2–8°C (36–46°F)
Expiration Date	Check <a href="#">product website</a> or QR code.

## Administration

Diluent	<b>Do not dilute.</b>				
Dose Volume– Primary/Additional	0.25 mL† (25 mcg dose)	N/A	0.5 mL (50 mcg dose)	0.5 mL (100 mcg dose)	N/A
Dose Volume–	<b>Do not use for</b>	0.2 mL†	<b>Do not use for</b>	<b>Do not use for</b>	<b>Do not use for</b>

<https://eziz.org/assets/docs/COVID19/IMM-1399.pdf>


# COVID Vaccine Trainings

Pfizer trainings:

<https://www.pfizermedicalinformation.com/en-us/medical-updates>

Moderna:


<https://app.livestorm.co/moderna-na-medical/moderna-office-hours-omicron-bivalent-booster>



Covid vaccines prevented more than 3.2 million deaths and 18.5 million hospitalizations in the U.S. from December 2020 through November 2022, according to an [analysis](https://www.commonwealthfund.org/blog/2022/two-years-covid-vaccines-prevented-millions-deaths-hospitalizations) published Tuesday by the Commonwealth Fund and Yale School of Public Health.


<https://www.commonwealthfund.org/blog/2022/two-years-covid-vaccines-prevented-millions-deaths-hospitalizations>

# Influenza Updates





# Influenza like Illness (ILI) - 2022 - 2023 Influenza season




## Outpatient Respiratory Illness Activity Map Determined by Data Reported to ILINet


This system monitors visits for respiratory illness that includes fever plus a cough or sore throat, also referred to as ILI, not laboratory confirmed influenza and may capture patient visits due to other respiratory pathogens that cause similar symptoms.

<https://www.cdc.gov/flu/weekly/index.htm>

# Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, October 2, 2022 – December 10, 2022




### Cumulative Rate of Laboratory-Confirmed Influenza Hospitalizations among cases of all ages, 2014-15 to 2022-23, MMWR Week 49



\*\*In this figure, weekly rates for all seasons prior to the 2022-23 season reflect end-of-season rates. For the 2022-23 season, rates for recent hospital admissions are subject to reporting delays, as shown in the shaded area. As hospitalization data are received each week, prior case counts and rates are updated accordingly.

# Influenza-Like Illness (ILI) Activity, 2019 to Present

New Mexico Department of Health (NMDOH) is collaborating with 21 ILI sentinel sites and 30 syndromic surveillance sites\* for the 2022-2023 season. Sites report weekly on the number of patients that present to their facility with influenza-like illness (ILI). That number is then divided by the total number of patients seen for any reason, resulting in percent of ILI activity. ILI is defined as fever of greater than or equal to 100° F and cough and/or sore throat.



data through 12/10/22

<https://www.nmhealth.org/about/erd/ideb/isp/>



## Preliminary In-Season Burden Estimates, 2022-2023



CDC estimates\* that, from **October 1, 2022** through **November 26, 2022**, there have been:

8.7 – 19 million  
flu **illnesses**



4.2 – 9.5 million  
flu **medical visits**



78,000 – 170,000  
flu **hospitalizations**




4,500 – 13,000  
flu **deaths**




<https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm>

# MPOX Updates



# US MONKEYPOX Trends

Daily Mpox Cases and 7 Day Daily Average




Data Table



# MPOX Cases in NM


## 54 MPOX Cases in NM






## Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons — 43 U.S. Jurisdictions, July 31–October 1, 2022

Weekly / December 9, 2022 / 71(49);1560–1564



Among JYNNEOS vaccine-eligible men aged 18–49 years in 43 U.S. jurisdictions, mpox incidence among unvaccinated persons was 9.6 times as high as that among persons who had received 2 vaccine doses and 7.4 times as high as that among persons who had received only the first dose. Preliminary evidence indicates no difference in protection between subcutaneous and intradermal administration routes.


# MPOX Vaccine in NM



NMDOH MPOX site:  
<https://www.nmhealth.org/about/phd/idb/mpv/>

online registration and  
scheduling is retiring.

Vaccine appointments  
available at NMDOH,  
Truman, SW Care or IHS



**MONKEYPOX**

How do I get vaccinated?


If you think you are at risk for Monkeypox and are interested in a vaccine


**REGISTER BY PHONE:**

Call the **NM Department of Health (NMDOH) Call Center** at **1-855-600-3453, Option 4** for a confidential consultation.

**REGISTER ONLINE:**

Visit: **monkeypoxnm.org**  
You will be invited to schedule a vaccine appointment based on your risk.



 For more information about monkeypox, visit:  
[nmhealth.org/about/phd/idb/mpv](https://www.nmhealth.org/about/phd/idb/mpv/)

# Resources





# COVID Vaccine Expiry Extensions

- **Pfizer** has received shelf-life extensions of all TRIS products (i.e., all mRNA COVID-19 vaccines including both monovalent and bivalent vaccines).
- Expiry is now 18 months from the date of manufacture (stored ULT frozen).
- Please use the [Pfizer-BioNTech COVID-19 Vaccine Expiry](#) tool to check expiration dates.
  
- **Moderna** has now received shelf-life extensions of all wave 1 and wave 2 monovalent COVID-19 vaccines (complete list below)
- Some of the lots are MOD 10 (ages 12+) and some are MOD 5 (ages 6-11)
- All Moderna lots that have received shelf-life extensions are for primary series use only.
- Please use the [Moderna Vial Expiration Checker](#) tool to check expiration dates.

<https://modernacovid19global.com/en-US/vial-lookup>

<https://lotexpiry.cvdvaccine.com/>



## COVID-19 Toolkit

We now have many tools to fight COVID: masking, vaccines, treatment, testing, and social distancing. We have reached a new place in New Mexico where we can lift nearly all public health requirements that prevented many COVID cases, hospitalizations, and deaths. It is now possible for us to manage COVID-19 in our homes and in our communities.

This toolkit provides COVID-19 support and guidance for New Mexico communities and individuals.

[DOWNLOAD THE FULL TOOLKIT - ENGLISH](#)

[DOWNLOAD THE FULL TOOLKIT - SPANISH](#)






Week Starting on:  
**11/27/2022**

Respiratory Infection	Total Results	Total Positives	Two Week Trend
COVID-19	11762	1236	*
Adenovirus	506	9	—
Chlamydia Pneumoniae	506	0	—
Human Metapneumavirus	506	8	—
Influenza A – not subtyped	8833	2095	↑
Influenza A H1	714	11	—
Influenza A H3	506	62	↑
Influenza B	8835	2	—
Mycoplasma Pneumoniae	506	0	—
Other Coronaviruses	506	4	—
Parainfluenza (1-4)	2024	31	—
Rhinovirus	506	54	↑
RSV	2522	639	↑


Total COVID-19 Samples  
**11,762**

Total Respiratory Samples  
(excluding COVID-19)  
**8,837**


Respiratory Infection by Age Group for Specified Week



Type of Respiratory Infection by Calendar Year



Respiratory Infection Over Time





Immunization Office Hours (weekly  
Thursdays @ 4pm) with Edward Wake


**Join on your computer or mobile app**

[Click here to join the meeting](#)



# CDC BOOSTER TOOL - updated

## Find Out When You Can Get Your Booster



Boosters are an important part of protecting yourself from getting seriously ill or dying from COVID-19. They are recommended for most people.

Use this tool to determine when or if you (or your child) can get one or more COVID-19 boosters.

[Find Out When to Get a Booster >](#)

This tool is intended to help you make decisions about getting COVID-19 vaccinations. It should not be used to diagnose or treat COVID-19.

[Restart](#)

[Stay Up to Date with COVID-19 Vaccines Including Boosters | CDC](#)

# COVID Vaccine Expiry Lookup Tools

- Moderna
  - <https://eua.modernatx.com/covid19vaccine-eua/providers/vial-lookup>
- Janssen
  - <https://vaxcheck.jnj/>
- Novavax
  - <https://us.novavaxcovidvaccine.com/hcp>
- Pfizer
  - <https://lotexpiry.cvdvaccine.com/>

# DOH Contact Information for Patients

CONTACT INFO	DESCRIPTION
<b>NMDOH Call Center: 1-855-600-3453</b>	Users who have questions or would like support with COVID vaccine registration and testing Taking Monkeypox questions and registering people for MPX Vaccine (Jynneos)
<b>ALTSD assistance: 1-800-432-2080</b>	For seniors and those with disabilities who need support with vaccine registration and scheduling.
<b>1-833-551-0518</b>	For non-health related COVID-19 questions
<a href="https://vaxviewnm.org">Vaxviewnm.org (state.nm.us)</a>	Access your immunization record (including “smart card”)

# DOH Contact Information for Providers

CONTACT INFO	DESCRIPTION
<b>Epidemiology and Response Division</b> call line: 505-827- 0006	Epidemiologist on call for guidance on any reportable diseases (monkeypox, measles, rabies, etc)
<b>COVID.Vaccines@doh.nm.gov</b>	COVID-19 Vaccine Record requests; Provider COVID-19 Vaccine Order status; NMSIIS assistance.
<b>COVID.Therapeutics@doh.nm.gov</b>	Provider questions regarding COVID therapeutics
<b>COVIDData.compliant@doh.nm.gov</b>	COVID-19 vaccine storage and handling questions, temperature log and onboarding Vaccine Plan submissions.
<b>COVID.testing-doh@doh.nm.gov</b>	For Provider questions on testing and test supplies





**HAPPY**  
*Holidays*